Scientists discuss the rationale for the combinational use and summarized the current data on the combinations of BTK inhibitors and venetoclax in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
[Biomarker Research]
6445212
BBBBBBBB
items
1
apa
0
default
asc
1
173638
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
